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1Chapter
Introductory Chapter: The 
Global Distribution of Human 
Histoplasmosis - An Overview
Felix Bongomin and Lauryn Nsenga
1. Introduction
Between 1906 and 1909, Dr. Samuel T. Darling described human histoplasmosis 
(of Darling or Darling’s disease) among three patients in the Canal Zone, Panama 
who had presented with severe emaciation, pancytopenia, intermittent fevers and 
splenomegaly – resembling kala-azar and disseminated tuberculosis, clinically [1]. Dr. 
Darling demonstrated numerous small, intracellular encapsulated micro-organisms in 
tissue specimens of his patients and named the organism, Histoplasma capsulatum [2].
H. capsulatum is a thermally dimorphic fungus, existing as a mould in 
the environment and as a small narrow-based budding yeast in the host at 
37°C. Environmental isolations of the fungus have been made from soil enriched 
with excreta from chicken, starlings, and bats [3, 4]. H. capsulatum species complex 
comprises of two distinct varieties, that is, H. capsulatum var. capsulatum (hereafter 
referred to as H. capsulatum) and H. capsulatum var. duboisii (hereafter referred to 
as H. duboisii) [5]. Epidemiologically, H. capsulatum is patchily distributed around 
the world, whereas H. duboisii is almost restricted to Sub-Saharan Africa [6]. 
Histologically, the yeast form of H. capsulatum is smaller, about 1–5 μm compared 
to the larger H. duboisii, which is about 5–20 μm [7]. Clinically, H. capsulatum 
is associated with protean manifestations; meanwhile H. duboisii mainly causes 
musculoskeletal and cutaneous manifestations [8, 9]. Both species complex are 
associated with pulmonary diseases; however, the absence of pulmonary lesions 
does not exclude the diagnosis of other forms of histoplasmosis [8].
Humans acquire histoplasmosis through inhalation of Histoplasma microconidia 
(spores) from abiotic environment. Majority of the immunocompetent individuals 
are asymptomatic, some develop self-limiting influenza-like syndromes and a vast 
minority develop disseminated disease, especially those with severe immunosup-
pression such as those with HIV/AIDS and those on biologic therapy [10, 11]. 
Subclinical infections can be demonstrated through histoplasmin skin testing while 
clinical disease through conventional culture and microscopy or histopathological 
analysis of the appropriate clinical specimen [12–14]. In this chapter, we aimed to 
overview the global epidemiology of histoplasmosis and also we touched briefly on 
its clinical manifestations, diagnosis, and treatment.
2. Global epidemiology
The global distribution of histoplasmosis and Histoplasma is incompletely 
understood [15]. The true burden of histoplasmosis in many areas of the world 
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remains unknown due to lack of diagnostics, awareness among clinicians, 
and in histoplasmosis not being a notifiable disease. Histoplasma inhabits soils 
enriched with bird and bat excreta, high nitrogen content with a neutral PH [16]. 
Occupational exposures among excavators and those at construction sites resulting 
into disruption of soil and inhalation of large inoculum of Histoplasma spores have 
been described [17].
Despite the global report of histoplasmosis, majority of the cases are reported 
from North and Latin America [6, 15, 18]. In North America, the Ohio and 
Mississippi river valleys and the Atlantic coastal states of Florida and New York 
have high rates of prior sub-clinical histoplasmosis based on histoplasmin skin 
tests [6, 15, 18]. Histoplasmosis in South and Central America is heavily driven 
by the HIV pandemic, and AIDS-associated histoplasmosis remains as common 
as tuberculosis in this region [19–21]. Imported and autochthonous cases of 
histoplasmosis have been described in Europe. Likewise in Africa, microfoci of 
histoplasmosis exist with reported large and small outbreaks have been attrib-
uted to histoplasmosis, but most infections are sporadic and imported cases 
from endemic areas have also been described [15, 22]. In review of literature of 
recently published data, chronic cavitary histoplasmosis is described as a com-
mon entity in endemic areas and commonly misdiagnosed as smear-negative 
tuberculosis [23].
In HIV population, globally, about half a million people get infected with 
Histoplasma infection every year. However, approximately 100,000 people develop 
disseminated disease [24, 25], with mortality rates if treated ranging between 30 to 
50% and 100% if not [20, 21, 26–29]. Accordingly, WHO has recognised as a killer 
of patients with advanced HIV and has currently recognised histoplasmosis as a 
neglected tropical diseases and has included Histoplasma antigen tests on the WHO 
essential diagnostic list [30].
Histoplasmosis is a major killer of HIV-infected patients in South and 
Central America [29, 31]. In 2012, about 6710–15, 657 cases of symptomatic 
HIV-associated histoplasmosis were estimated in Latin America, with areas such 
as Central America, the northernmost part of South America, and Argentina 
having a prevalence above 30% and incidence >15 cases per 100 people  living 
with HIV, resulting to about 671–9394 deaths related to histoplasmosis, 
 compared with 5062 deaths related to tuberculosis reported in the region [32]. 
In Brazil, AIDS-associated disseminated histoplasmosis had a mortality as 
high as 33.1% [27]. In Guatemala, 31.2% of patients with advanced HIV had 
 histoplasmosis [33].
Excluding the Indian sub-continent, 407 cases of histoplasmosis in South East 
Asia have been reported [34]. Most cases (255 (63%)) were disseminated histoplas-
mosis and 177 (43%) cases were HIV associated [34]. A similar study was reported 
from Bangladesh were 22 of the 26 cases had disseminated histoplasmosis, 4 had 
HIV, and 9 patients were misdiagnosed for tuberculosis [35]. In a more recent study, 
around 1692 cases of histoplasmosis were reported from Asian countries; India (623 
cases), China (611 cases), and Thailand (234 cases) [36].
Oladele and colleagues described 470 cases of histoplasmosis in Africa between 
1952 and 2017 [9]. In Nigeria, 4.4% of 750 subjects from across the country tested 
positive for histoplasmin skin test [13]. In the East African region, a study from 
Northern Tanzania retrospectively identified 0.9% cases of probable histoplasmosis 
among febrile inpatients, ~66.7% of whom were HIV-infected and ~77.8% were 
clinically misdiagnosed as tuberculosis or bacterial pneumonia [37]. In Uganda, 
1.3% (2/151) of HIV-infected persons with suspected meningitis were serum 
Histoplasma IgG positive [38].
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3. Syndromes of histoplasmosis
3.1 Pathogenesis
Following inhalation of Histoplasma microconidia, it rapidly transforms from 
the mycelial into the yeast form [17, 39]. Innate response involves early migration 
of the neutrophils toward the yeast; however, they are unable to destroy it. Alveolar 
macrophages then engulf the fungi but can’t destroy it either, but instead the yeast 
multiplies inside it [17, 39]. In immunocompetent individuals, T-cell-mediated 
immunity is activated, and the T-cells release pro-inflammatory cytokines which 
activate mononuclear phagocytes, hence producing tumour necrotic factor α (TNF-
α) and more cytokines [17, 39]. Well-defined granulomas are formed. H. capsulatum 
may disseminate to other organs but on activation of cellular immunity, it is quickly 
controlled, and individuals have a quick recovery or develop latency. Therefore, 
most infections go unnoticed [17, 40].
However in immunosuppressed individuals or individuals exposed to large inocu-
lum, T-cell-mediated immunity may not contain the infection, as poorly circum-
scribed granulomas are usually formed, and progressive dissemination may occur 
[5, 41]. Patients become symptomatic and may require hospitalisation for antifungal 
treatment and supportive care occur [5, 41]. The most common cause of dissemi-
nated progressive disease is reactivation of latent pulmonary infection [17, 40].
3.2 Clinical manifestation
Histoplasmosis has varied presentation depending on the host immune status 
and the inoculum size. In immunocompetent individuals exposed to a low infec-
tious inoculum, individuals are usually asymptomatic or experience a mild flu-like 
respiratory illness [41]. In most cases, these cases go unnoticed unless patients are 
being investigated for a suspected outbreak. Among immunocomptent travellers 
exposed to highly infectious (large inocula) of Histoplasma, acute episodes of pneu-
monia occurring either immediately or a few weeks later have been described [42].
Individuals whose cellular immunity is compromised for number of reasons for 
example HIV infection, organ transplant, immunosuppressive therapy or biological 
therapy, i.e., anti-TNF-α drugs usually present with a disseminated form of histo-
plasmosis [10, 11, 43]. Disseminated histoplasmosis presents with fever, fatigue, 
malaise, anorexia, weight loss, and respiratory symptoms [1, 5]. Lymphadenopathy, 
hepato-spenomegaly, mulluscum contagiosum like skin lesions, and oral lesions are 
common. Shock with multi-organ failure and coagulopathy are terminal events and 
are commonly misdiagnosed for bacterial sepsis [1, 5].
In acute pulmonary histoplasmosis, almost all patients are asymptomatic or 
experience a self-limiting infection that often goes undetected. Symptoms appear in 
about 10% of patients, last for less than 2 weeks and are often misdiagnosed. Such 
patients are usually at extremes of age, having underlying co-morbidities or immu-
nocompromised. Common symptoms suggestive of acute pulmonary histoplasmo-
sis include non-productive cough, dyspnoea, headache, malaise, fever, chills, and 
chest pain that are due to mediastinal lymph node enlargement [40]. Less common 
symptoms include rheumatologic complaints arthralgia, arthritis, erythema nodo-
sum, erythema multiforme, especially in females [40]. Chest radiographs typically 
show diffuse pneumonitis, hilar and/or mediastinal lymphadenopathy.
Chronic pulmonary histoplasmosis includes chronic cavitary pulmonary histo-
plasmosis and Histoplasma nodule (histoplasmoma) [23]. It is a progressive disease 
occurring over a period of months to years. Chronic pulmonary histoplasmosis 
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occurs in patients with structural lung diseases. Haemoptysis is common among 
patients with chronic pulmonary histoplasmosis, noted in up to a third of the cases. 
Chest radiography reveals calcified mediastinal and hilar lymph nodes of normal 
size along with infiltrates that evolve over time, first from focal or diffuse infil-
trated to consolidations, cavitations, interstitial fibrosis, and pleural thickening, 
similar to patients chronic pulmonary aspergillosis and pulmonary tuberculosis 
[23]. Uncommon complication of pulmonary histoplasmosis includes mediastinitis, 
manifesting as adenitis, granulomatosis, and fibrosing [5].
Acute progressive disseminated histoplasmosis is rare except in extremes of age 
(less than 1 year old and more than 50 years old) and those with significant immu-
nocompromise, for example, HIV patient with CD4 count <200 μ/l [11, 29, 32]. 
Acute progressive disseminated histoplasmosis may proceed after acute pulmonary 
histoplasmosis or re-activation of latent pulmonary lesion after a long period 
of latency. Patients with acute progressive disseminated histoplasmosis present 
with systemic (constitutional-fevers, weight loss, and weakness) and pulmonary 
symptoms. Focal or diffuse multi-organ is typical, with predilection for the reticu-
loendothelial system and the central nervous system. Physical examinations may 
reveal painful oropharyngeal ulceration, hepato-splenomegaly, and diffuse lymph-
adenopathy [5, 10, 17, 44].
4. Diagnosis
A high index of clinical suspicion is required for timely diagnosis, given the 
non-specific nature of presentation of histoplasmosis. A robust history, physical 
examination, and tailored investigation are needed simultaneously for a definitive 
diagnosis. Although histopathology and culture remain the gold standard for diag-
nosis of histoplasmosis, advancements in technology have provided Histoplasma 
antigen detection which is reliable, non-invasive, and highly sensitive [14, 41]. 
Misdiagnosis of acute progressive disseminated histoplasmosis has been linked to 
high mortality rates. Up to 42% mortality if initiation of treatment is delayed and as 
high as 100% if antifungal therapy is not given at all [21].
H. capsulatum can be cultured from sputum, blood, bone marrow, tissue biopsy 
or brochoalveolar lavage (BAL). Culture needs a period of 4–6 weeks to be appre-
ciable as white-fluffy mould. The culture is most sensitive in patients with chronic 
pulmonary histoplasmosis (sputum) or progressive disseminated histoplasmosis 
(bone marrow) [45, 46]. Cultures have limitations such as long-turn around time, 
suboptimal sensitivity and require Biosafety level 3 facilities [14, 41]. Sensitivity of 
culture is about 70–85% [10].
Histopathology demonstrates the presence of caseating and non-caseating 
granulomas. Then the yeast is confirmed by special fungal stains, commonly, 
Gomori-methenamine silver, Giemsa or periodic acid-Schiff stains. H. capsulatum 
yeasts are about 1–4 μm in diameter, ovoid shape, predominantly intracellular 
(within macrophage) and giant cells with characteristic, single-celled narrow-based 
budding [7]. As a limitation, histopathology requires highly skilled personnel who 
may not be accessible across all levels of health care. Histopathology has a sensitiv-
ity of 70–80%, depending on the quality of the sample and the experience of the 
pathologist [10]. Because of the above limitations, we have advocated for universal 
access to rapid testing for histoplasmosis (antigen or PCR/molecular) [30, 47].
Histoplasma antigen detection is the most sensitive method for diagnosis. The 
sensitivity of the MVista® Quantitative Histoplasma antigen enzyme immunoassay 
is 95–100% in urine, over 90% in serum and bronchoalveolar lavage (BAL) antigen 
and 78% in cerebral spinal fluid (CSF) [10]. Sensitivity of antigen testing differs 
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with respect to the clinical picture. A sensitivity of 91.8% in disseminated histoplas-
mosis, 87.5% in chronic pulmonary histoplasmosis, and 83% in acute pulmonary 
histoplasmosis has been reported [45, 46, 48]. Antigen testing can be used to 
monitor improvement on therapy, determine prognosis of patients, and ascertain 
possibility of relapse especially for patients with co-infections like tuberculosis [45, 
46, 48]. The limitation of antigen testing is in its cross reactivity with organisms 
that have the same class of cell wall galactomannan such as, Blastomyces, Aspergillus, 
Talaromyces, Coccidioides, and Paracoccidioides spp. [45, 46, 48].
Antibody detection is done by different methods. The two standard assays are 
complement fixation and immunodiffusion [14]. Immunodiffusion detects the 
presence of antigens C, H and M precipitin bands. The C antigen suggests cross 
reactivity between fungal species; H antigen indicates active infection; and M 
antigen shows acute, subacute or chronic infection. Complement fixation assay 
generates antibody titres. The sensitivity of antibody detection by immunodiffusion 
or complement fixation was between 60 and 70% [10]. Immunodiffusion assay is 
more specific than complement fixation assay.
Polymerase Chain Reaction (PCR) assay has been widely accepted for detection 
of reservoirs for H. capsulatum in the environment [43, 49]. Bone marrow and blood 
specimen have high sensitivity especially in patients with disseminated disease but 
less in immunocompetent [50, 51]. Respiratory biopsies and samples have shown 
good sensitivity [14].
5. Treatment
Acute and subcute pulmonary histoplasmosis are usually self-limiting hence 
do not require therapy [43]. But if symptoms persist for more than a month, then 
oral itraconazole is given for a period of 6–12 weeks [43]. Cases of histoplasmosis-
related acute respiratory distress syndrome may benefit from adjunctive corticoste-
roid steroid therapy.
In chronic pulmonary histoplasmosis, patients require long-term oral treat-
ment with itraconazole for about 12–24 months or until radiological improvement 
on follow-up chest imaging [43]. Relapse is common following discontinuation of 
antifungal treatment [43].
In acute progressive disseminated histoplasmosis, induction therapy with liposo-
mal amphotericin B for 1–2 weeks (or 2–6 weeks for central nervous system histo-
plasmosis) followed by a step-down therapy with oral itraconazole for 12 months 
[43]. Life-long oral itraconazole therapy is advised for patients with on-going 
immunosuppression. Liposomal amphotericin B is associated with better outcome 
than any other preparations of amphotericin B [52].
6. Conclusions
Human histoplasmosis is of global distribution, with patchy areas of high ende-
micity. The protean manifestations of histoplasmosis require a heightened index 
of clinical suspicion for early diagnosis and institution of appropriate treatment. 
Antigen-based diagnostics are the cornerstone for microbiological confirmation 
of histoplasmosis, given their high sensitivity and specificity, short-turn around 
time and non-invasiveness. Treatment is reserved for those with moderate to severe 
forms of pulmonary diseases, the immunocompromised, and those with dis-
seminated diseases. Itraconazole singly or as a follow through treatment following 
amphotericin B are the basis of antifungal treatment.
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